Category: Revolutions Medical Corp.
Revolutions Medical sues former president & director Thomas O'Brien for alleged collusion with Richard Theriault, whom the company also sued.
Revolutions Medical (PINK:RMCP) filed a lawsuit against former president & director Thomas O'Brien, accusing him of taking bribes from and leaking confidential information to another lawsuit target, Richard Theriault.
Revolutions Medical plans to "vigorously" defend itself against an SEC lawsuit, claiming allegations that the company issued fraudulent accounts of its safety syringe production were spurred by libelous claims from a pair of aggressors.
The Securities & Exchange Commission filed a civil complaint in federal court against safety device and software maker Revolutions Medical (PINK:RMCP) over handful of allegedly "misleading press releases" the company issued in 2010 and 2011, according to regulatory filings.
A federal appeals court upholds a legal win for Medtronic in a personal injury lawsuit filed after its SynchroMed EL pain pump left an Arizona man paralyzed.
Medtronic (NYSE:MDT) won another personal injury lawsuit based on the preemption doctrine it helped create in the U.S. Supreme Court's Riegel v Medtronic decision in 2008.
Shire plc doubles down on its $750 million buyout of Advanced Biohealing with Pervasive Therapeutics and its endothelial cell technology; also, orthopedic bellwether Biomet's Q3 results signal sector growth; McKesson beats out rivals for $32B VA deal; Insulet expands OUS distribution deal; Revolutions Medical inks Korean distribution deal; Pluromed pays back $500k Mass. loan; plus, a Funding Roundup and analysts' ups and downs.
Shire (NSDQ:SHPGY) said it agreed to acquire Pervasis Therapeutics and its endothelial cell technology for an undisclosed amount.
Is hedge fund giant David Tepper's new stake in Boston Scientific an indication that it's ripe for a private equity buyout?; also, OTC lists Titan Medical; Burrill & Co. opens in Taiwan; MGT Capital plans reverse split to stay on NYSE; plus a Deals Roundup, a Funding Roundup and analysts' ups and downs.
Billionaire hedge fund manager David Tepper, of Appaloosa Management, bought 7.8 million shares of Boston Scientific stock during the 4th quarter, according to regulatory filings, for a stake with a market value of $41.6 million as of Dec. 31.
Synthes CEO Michel Orsinger will land a $51.9 million payout as part of a $21.3 billion buyout by Johnson & Johnson.
Synthes CEO Michel Orsinger
Synthes CEO Michel Orsinger will land a $52 million payout to give up the corner office as part of the Swiss orthopedic device maker's $21.3 billion buyout by med-tech titan Johnson & Johnson (NYSE:JNJ).
The deal, slated to close in early 2012, includes a $51.9 million payout to Orsinger for leaving Synthes and a multimillion-dollar stock package for his new position with Johnson & Johnson.